Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM

Abstract

BackgroundMiR-106a is frequently down-regulated in various types of human cancer. However the underlying mechanism of miR-106a involved in glioma remains elusive.MethodsThe association of miR-106a with glioma grade and patient survival was analyzed. The biological function and target of miR-106a were determined by bioinformatic analysis and cell experiments (Western blot, luciferase reporter, cell cycle, ntracellular ATP production and glucose uptake assay). Finally, rescue expression of its target SLC2A3 was used to test the role of SLC2A3 in miR-106a-mediated cell glycolysis and proliferation.ResultsHere we showed that miR-106a was a tumor suppressor miRNA was involved in GBM cell glucose uptake and proliferation. Decreased miR-106a in GBM tissues and conferred a poor survival of GBM patients. SLC2A3 was identified as a core target of miR-106a in GBM cells. Inhibition of SLC2A3 by miR-106a attenuated cell proliferation and inhibited glucose uptake. In addition, for each biological process we identified ontology-associated transcripts that significantly correlated with SLC2A3 expression. Finally, the expression of SLC2A3 largely abrogated miR-106a-mediated cell proliferation and glucose uptake in GBM cells.ConclusionsTaken together, miR-106a and SLC2A3 could be potential therapeutic approaches for GBM.

MicroRNA‐124‐3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targeting PIM1 in astrocytoma

“…MicroRNA‐7‐5p inhibits cellular growth and glucose metabolism by directly targeting insulin‐like growth factor 1 receptor in glioma . MicroRNA‐106a‐5p inhibits glioma cell glucose uptake by targeting solute carrier family 2 (facilitated glucose transporter), member 3 in glioblastoma . MicroRNA‐143‐3p inhibits glycolysis and promotes differentiation by targeting hexokinase 2 in glioblastoma stem‐like cells .…”

“…(46) MicroRNA-106a-5p inhibits glioma cell glucose uptake by targeting solute carrier family 2 (facilitated glucose transporter), member 3 in glioblastoma. (47) MicroRNA-143-3p inhibits glycolysis and promotes differentiation by targeting hexokinase 2 in glioblastoma stem-like cells. (48) MicroRNA-451a regulates cellular adaptation to metabolic stress in glioma by regulating the serine/threonine kinase 11/AMP-activated protein kinase pathway.…”

Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance

“…TCF7 is an anti-apoptotic gene76 and was 17.66-fold down-regulated. SLC2A3 plays a role in carcinogenesis77 and was 13.64-fold up-regulated in CEM/ADR5000 cells.…”

Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma

“…According to the previous research, abnormal miR-106a expression had been reported to be contributed to several tumors, but the expression pattern of miR106a seemed to differ among human malignancies. For instance, upregulation expression of miR-106a was described in several types of cancers, such as gastric cancer [33,25], colon cancer [34], pancreatic cancer [26], and ovarian cancer [35], whereas its downregulation expression was also reported in glioma [36]. However, the knowledge about miR-106a in HCC is still limited.…”